血清游离轻链检测替代24小时尿轻链监测用于可测尿单克隆蛋白的多发性骨髓瘤患者
研究纳入122例基线可测尿M蛋白且已证实疾病进展的多发性骨髓瘤患者,分析系列血清游离轻链差值(dFLC)能否替代系列24小时尿M蛋白检测来监测进展。结果显示,以尿M蛋白定义的进展时,中位dFLC相对增幅为110%(IQR:55-312),中位绝对增幅为74 mg/dL;89%患者dFLC增幅≥25%,94%患者绝对增幅>10 mg/dL,98%满足至少一条标准。作者结论:系列dFLC可替代系列24小时尿蛋白评估用于监测进展;当dFLC自最低点绝对增幅>10 mg/dL时,再行24小时尿收集以按IMWG标准确认进展。
要点
- 以尿M蛋白定义进展时,中位dFLC相对增幅110%(IQR:55-312),绝对增幅74 mg/dL。
- 89%患者dFLC增幅≥25%,94%绝对增幅>10 mg/dL,98%满足至少一条标准。
- 作者结论:系列dFLC可替代系列24小时尿蛋白评估监测进展;dFLC绝对增幅>10 mg/dL时再收集24小时尿确认进展。
核心结论
- 作者结论:系列dFLC评估可替代系列24小时尿蛋白评估用于骨髓瘤监测中的疾病进展监测。
- 作者建议:当患者dFLC自最低点绝对增幅>10 mg/dL时,可行24小时尿收集以按IMWG标准记录疾病进展。
研究设计与样本
- 研究纳入122例基线可测尿M蛋白、已证实疾病进展且具有系列尿M蛋白和血清FLC检测结果的患者。
主要发现
- 以尿M蛋白定义的进展时,dFLC中位相对增幅为110%(IQR:55-312),中位绝对增幅为74 mg/dL。
- 以尿M蛋白定义的进展时,89%患者dFLC增幅≥25%,94%患者dFLC绝对增幅>10 mg/dL,98%患者满足至少1条标准。
- 在基线可测血清FLC的118例患者中,89%患者dFLC增幅≥25%,97%患者dFLC绝对增幅>10 mg/dL,98%患者满足1条标准。
临床怎么用
- 作者结论:系列dFLC评估可替代系列24小时尿蛋白评估用于骨髓瘤监测中的疾病进展监测。
- 作者建议:当患者dFLC自最低点绝对增幅>10 mg/dL时,可行24小时尿收集以按IMWG标准记录疾病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Detection of myeloma progression (PD) relies on serial 24-h urinary M protein measurements in patients without measurable serum M spike. We examined whether serial difference free light chain (dFLC) levels could be used as a surrogate for serial 24-h urine M protein measurements in monitoring for PD in patients with baseline measurable urine M protein. We studied 122 patients who had serial measurement of urine M protein and serum FLC and had demonstrated PD. The median increase in dFLC with progression as defined by urine M spike was 110% (IQR: 55-312) and median absolute increase was 74 mg/dL; while 89% of patients had dFLC increase ≥ 25%, 94% had absolute increase in dFLC > 10 mg/dL, and 98% met at least 1 of these 2 criteria at PD. In patients with baseline measurable serum FLC (n = 118), 89% had increase in dFLC ≥ 25%, 97% had dFLC increase of > 10 mg/dL, and 98% had 1 of the 2. We conclude that serial dFLC assessments can be used in place of serial 24-h urine protein assessments during myeloma surveillance to monitor for PD. Once patients have an absolute increase in dFLC of >10 mg/dL from the nadir, a 24-h urine collection can then be assessed to document PD as per the International Myeloma Working Group criteria.
引用
- Tschautscher M, Rajkumar V, Dispenzieri A, et al. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Am J Hematol. 2018. PMID: 30016549. doi:10.1002/ajh.25215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。